Drug intelligence / Profile preview

NBI-640756

Development stage: Unknown
Lead developer: Neurocrine Biosciences
Modality: Small Molecules

Overview

NBI-640756 is an investigational **small molecule** therapeutic discovered and developed by Neurocrine Biosciences for **essential tremor**. Public company materials describe it as a novel compound that showed promise in preclinical models of essential tremor and entered a Phase 1 single-dose safety, tolerability, and pharmacokinetic study in healthy volunteers. The specific molecular target, detailed mechanism of action, formulation details, and any commercial brand name have not been publicly disclosed in the sources reviewed.

Beyond the preview

Go deeper on NBI-640756.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NBI-640756.

Explore the full profile